新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » 高血压 » Actelion治疗肺动脉高血压新药Opsumit获得FDA通过

Actelion治疗肺动脉高血压新药Opsumit获得FDA通过

来源:生物谷 2013-10-23 21:53

2013年10月23日讯 /生物谷BIOON/ --上周,Actelion公司开发的用于治疗肺动脉高血压的新药Opsumit获得FDA通过。本周一公司股价应声上涨。Opsumit是Actelion公司现有的Tracleer的后续版本。此次FDA的批准本来就在Actelion的预料之中。Opsumit的各项研究数据都十分理想,一旦上市,这种药物的价格将和现有的Tracleer持平。

近年来肺动脉高血压治疗领域的竞争日趋激烈。就在不久前,拜耳公司的Adempas刚刚获得FDA的批准。而2007年被FDA批准的Gilead公司的Letairis更是挤占了Tracleer的不少市场份额。可以预期,今后该领域市场的竞争将更趋激烈。(生物谷Bioon.com)

详细英文报道:

Late on Friday the FDA came through with an approval for Actelion's pulmonary arterial hypertension (PAH) drug Opsumit (macitentan), its next-gen successor to the franchise drug Tracleer. And on Monday the Swiss company's shares shot up 7% on the news.

The approval comes as no great surprise. The company ($ATLN) had been steadily doing the rounds with regulators, armed with positive late-stage data. The lead-up to the Phase III read out, though, had precipitated considerable angst among some of the analysts covering the Swiss company. Actelion gets the bulk of its revenue from the PAH drug Tracleer and had to have a score here in advance of a loss of patent protection.

Opsumit will carry a boxed warning alerting patients and physicians that the drug should not be used in pregnant women because it can harm the developing fetus. But the FDA release made no mention of a required liver test in the warning, something some analysts felt would have blunted sales.

A spokesperson for the company told FierceBiotech that the new therapy will be priced similarly to Tracleer.

PAH drug development has been a busy field in recent years. Just days ago Bayer won an FDA approval for its lung disease drug Adempas (riociguat). United Therapeutics ($UTHR), though, recently picked up its second CRL from the FDA for an oral version of Remodulin. Gilead's ($GILD) Letairis--approved in 2007--has meanwhile been eating into Tracleer's market.

Actelion is staying focused on R&D for PAH. The next drug in its pipeline is the Phase III treatment selexipag. Actelion licensed the ex-Japan rights to the drug from Nippon Shinyaku and expects to report late-stage data in mid-2014.

"Today's approval of Opsumit by the FDA is providing the PAH community with a unique treatment option, the only oral PAH medicine that has proven to delay disease progression," noted Actelion CEO Jean-Paul Clozel, who had to endure an unsuccessful shareholder revolt while he stayed the course on Opsumit's development. "Over the last 14 years, Actelion has worked tirelessly to first discover and then develop Opsumit in the largest, longest and first-ever outcome study in PAH."

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库